We are proud to announce that Biomedical Advanced Research and Development Authority (BARDA) has selected Kaléo to develop the next generation pralidoxime chloride (2-PAM) auto-injector as a medical countermeasure against nerve agent poisoning.
“The contract tasks Kaléo with developing a 2-PAM auto-injector for U.S. Food and Drug Administration (FDA) approval within 3 years, with an ultimate goal of enabling later procurement of the 2-PAM auto-injectors for BARDA’s CHEMPACK program,” said Mark Herzog, Kaleo’s VP for Global Corporate Affairs, Defense and Homeland Security.
Kaléo is a market leader in emergency use auto-injectors with more than 12 million devices manufactured to meet the FDA’s standard of 99.999% device reliability.
Read our full announcement here: https://bit.ly/2PAM_AI
#Kaleo #MCM #medicalcountermeasure #CHEMPACK #BARDA #publichealth
President at Wannarka Consulting
8mointeresting, send me a note. Jerry